ArticleBMC research notes2025
Loss of measles, mumps, and rubella immunity in pediatric cancer survivors following chemotherapy.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPediatric cancer survivors are at increased risk for vaccine-preventable diseases due to treatment-related immunosuppression. This study aimed to assess serological status for measles, mumps, and rubella (MMR) following chemotherapy and identify factors associated with antibody loss.
resultsFifty-four pediatric cancer survivors (mean age 12.5 years) were evaluated at a median of 2.5 years (IQR 1.2, 5.4) after completing chemotherapy. All participants had received at least one MMR dose before their cancer diagnosis and had completed treatment at least six months prior. Overall, 43 patients (79.6%) were seronegative for at least one MMR component. Seronegativity was highest for measles (64.8%), followed by mumps (55.6%) and rubella (35.2%). Measles seronegativity was significantly associated with a longer interval since chemotherapy (> 5 years; p = 0.04) and older age at receipt of the second MMR dose (mean 86.4 vs. 44.9 months; p = 0.002). No significant associations were observed for mumps or rubella seronegativity. These findings indicate a substantial decline in MMR immunity after chemotherapy and support the incorporation of routine post-chemotherapy revaccination into survivorship care, especially in settings where serologic testing is not readily available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.